04/25/2024 8:10 AM | Eiger BioPharmaceuticals (Subject) Nasdaq Stock Market LLC (Filed by)
| Form 25-NSE | |
04/08/2024 4:19 PM | Eiger BioPharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
04/01/2024 3:45 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
04/01/2024 3:45 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
04/01/2024 3:48 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
04/01/2024 3:48 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
04/01/2024 3:50 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
|
04/01/2024 3:51 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
04/01/2024 3:53 PM | Eiger BioPharmaceuticals (Filer)
| Form S-8 POS | |
04/01/2024 3:18 PM | Eiger BioPharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/14/2024 9:55 AM | AMERIPRISE FINANCIAL INC (Filed by) Eiger BioPharmaceuticals (Subject)
| Form SC 13G/A | |
01/08/2024 6:00 AM | Eiger BioPharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/04/2024 7:45 AM | Eiger BioPharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/04/2023 5:01 AM | Arkin Moshe (Filed by) Eiger BioPharmaceuticals (Subject)
| Form SC 13D/A | |
12/01/2023 3:02 PM | Eiger BioPharmaceuticals (Filer)
| Form PRE 14A | |
11/24/2023 5:01 AM | Arkin Moshe (Filed by) Eiger BioPharmaceuticals (Subject)
| Form SC 13D | |
11/02/2023 8:54 PM | Eiger BioPharmaceuticals (Subject) Propel Bio Management, LLC (Filed by)
| Form SC 13D/A | |
11/02/2023 8:21 PM | Eiger BioPharmaceuticals (Issuer) KAYNE RICHARD A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/02/2023 8:14 PM | Eiger BioPharmaceuticals (Issuer) KAWAS LEEN (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/30/2023 3:51 PM | Eiger BioPharmaceuticals (Issuer) KAWAS LEEN (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
10/20/2023 3:29 PM | Eiger BioPharmaceuticals (Subject) Propel Bio Management, LLC (Filed by)
| Form SC 13D | |
09/28/2023 3:54 PM | Eiger BioPharmaceuticals (Subject) Propel Bio Management, LLC (Filed by)
| Form SC 13G/A | |
09/12/2023 3:42 PM | Eiger BioPharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/05/2023 8:35 PM | Choong Ingrid (Reporting) Eiger BioPharmaceuticals (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
09/05/2023 8:38 PM | Choong Ingrid (Reporting) Eiger BioPharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/15/2023 5:00 AM | Eiger BioPharmaceuticals (Subject) Propel Bio Management, LLC (Filed by)
| Form SC 13G | |
07/07/2023 3:35 PM | BlackRock Inc. (Filed by) Eiger BioPharmaceuticals (Subject)
| Form SC 13G/A | |
07/06/2023 4:37 PM | Apelian David (Reporting) Eiger BioPharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/30/2023 3:16 PM | Eiger BioPharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2023 3:30 PM | Eiger BioPharmaceuticals (Issuer) Vollins James (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |